LB Pharmaceuticals Inc
LBRX
$14.90
-$0.61-3.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.83M | 15.33M | 13.66M | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.21M | 53.50M | 64.83M | -- | -- |
| Operating Income | -32.21M | -53.50M | -64.83M | -- | -- |
| Income Before Tax | -29.43M | -52.04M | -63.10M | -- | -- |
| Income Tax Expenses | 1.00K | 1.00K | 1.00K | -- | -- |
| Earnings from Continuing Operations | -29.43 | -52.04 | -63.10 | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.43M | -52.04M | -63.10M | -- | -- |
| EBIT | -32.21M | -53.50M | -64.83M | -- | -- |
| EBITDA | -31.97M | -53.33M | -64.74M | -- | -- |
| EPS Basic | -116.88 | -161.39 | -205.90 | -- | -- |
| Normalized Basic EPS | -73.75 | -61.84 | -90.52 | -- | -- |
| EPS Diluted | -116.88 | -161.39 | -205.90 | -- | -- |
| Normalized Diluted EPS | -73.75 | -61.84 | -90.52 | -- | -- |
| Average Basic Shares Outstanding | 1.01M | 755.40K | 753.20K | -- | -- |
| Average Diluted Shares Outstanding | 1.01M | 1.01M | 1.00M | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |